Abstract 957P
Background
So far there is no neoadjuvant therapy recommended by major hepatocellular carcinoma (HCC) guidelines. In other malignancies, ICIs in the neoadjuvant setting have shown better outcomes than in the adjuvant setting, and the combination of radiation therapy to ICIs incrementally improves the systemic response to ICIs. Neoadjuvant therapy of ICIs plus stereotactic body radiotherapy (SBRT) has shown promising results in several types of solid tumours but not HCC.
Methods
This is a phase Ib clinical trial of neoadjuvant SBRT plus PD-1 (tislelizumab) in HCC patients (pts). Prior to resection, pts receive 8 Gy × 3 SBRT with 2 cycles of PD-1. HCC resection is scheduled 4 weeks after the second PD-1, followed by adjuvant PD-1 for up to 1 year. We plan to enrol 20 participants in this trial. The primary study endpoints include the surgery delay over 6 weeks or later, ORR on pre-resection imaging, pathologic response (pCR) rate, safety and tolerability of the sequential SBRT/PD-1. The secondary endpoints are DFS and OS rates every 3 or 6 months after the hepatic resection.
Results
By 10th May 2023, 11 pts were enrolled, all were BCLC A stage. One pt was excluded due to the protocol violation, in other 10 pts, one just starts the adjuvant therapy, two have completed the neoadjuvant therapy and waiting for the scheduled resection, all other 7 pts have completed the resection, and no surgery delay accrued; DCR reached 100% (RECIST: 1 PR, 6 SD; mRECIST: 1 CR, 2 PR, 3 SD, 1 CR+SD ); pCR was confirmed in two tumors; So far the safety of neoadjuvant SBRT+PD-1 was satisfied, grade 1 to 2 TRAEs, mainly anemia and white blood cell decreasing were common; grade 3 TRAE occurred in 3 pts (1 granulocytopenia and 2 elevated transaminase), but all well-tolerated. One pt developed recurrence 9 months after surgery (RF ablation), all other 6 pts are still in DFS. Table: 957P
Pt # | age (Y) | gender | tumor size (cm) | BCLC stage | RECIST | mRECIST | interval between 2nd PD-1 and surgery | pCR (Y/N) | TARE over grade 3(Y/N) | survival |
1 | 70 | F | S7:2.4×2.2 | A | SD | SD | 31 | N | N | Recurrence/RFA |
2 | 74 | M | S4a:1.6; S2:1.2 | A | SD | S4a:CR; S2:SD | 28 | S4a: Y; S2:N | No | DFS |
3 | 64 | M | S8:1.8×1.6 | A | SD | SD | 28 | N | Y | DFS |
4 | 51 | M | S7/8:6.0×6.1 | A | PR | PR | 26 | Y | Y | DFS |
5 | 70 | M | S4/5:3.7×4.1 | A | SD | PR | 40 | N | N | DFS |
6 | 52 | M | S6/7:4.1×4.0 | A | SD | CR | 28 | N | Y | DFS |
7 | 70 | F | S6:3.3 | A | SD | SD | 34 | N | N | DFS |
8 | 48 | F | S8:2.2×1.7 | A | PR | CR | N | |||
9 | 56 | M | S6:2.9×2.4 | A | N | |||||
10 | 54 | M | S6:4.8×3.3; S8:2.2×1.8 | A | N |
Conclusions
The safety and clinical significance of radiotherapy plus PD-1 as the neoadjuvant therapy in HCC needs further exploration.
Clinical trial identification
NCT05185531.
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
The Key Research and Development Program of Shandong (Major Science & Technology Innovation Project), 2021SFGC0501. The reported trial is partly funded by BeiGene.
Disclosure
L. Zhao: Financial Interests, Personal, Speaker’s Bureau: Innovent, Hengrui Medicine, MSD, Roche, Bayer; Financial Interests, Personal and Institutional, Speaker’s Bureau. All other authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18